Baudax Bio Long Term Debt

Baudax Bio (BXRX) currently reports a long-term debt of $2.5M as of September 2023. That compares with $2.2M in the prior-year period — up 16.2% year over year. Use the charts on this page to explore Baudax Bio's long-term debt history and peer comparisons.

Baudax Bio's long-term debt increased from $2.2M to $2.5M — a 16.2% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Baudax Bio reported $2.5M in long-term debt as of September 2023. That compares with $2.2M in the prior-year period — up 16.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $2.5M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Baudax Bio, and consider following BXRX for alerts when major investors trade the stock.

Baudax Bio is classified in the Healthcare sector. On long-term debt, it currently shows $2.5M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BXRX with unrelated industries.